BIO Reaches Out To China, Encourages Harmonization
This article was originally published in PharmAsia News
Executive Summary
WASHINGTON - Chinese officials are in the process of building the country's biotech regulatory framework, and foreign and domestic companies see opportunities to help shape the country's path toward becoming a major biotech market
You may also be interested in...
BIO President Jim Greenwood Says Indian Biosimilars Welcome In U.S. Market: An Interview With PharmAsia News (Part 2 of 2)
WASHINGTON - BIO President Jim Greenwood recently returned from a trip across India aimed at drumming up interest in the BIO India Partnering Conference in September 2010; he touted India's burgeoning innovative biotech industry and discussed the growing interest of BIO in seeking new or expanded partnerships with Indian firms.
BIO President Jim Greenwood Says Indian Biosimilars Welcome In U.S. Market: An Interview With PharmAsia News (Part 1 of 2)
WASHINGTON - BIO President Jim Greenwood recently returned from a barnstorming trip across India to drum up interest for the BIO India Partnering Conference in September 2010, where he touted India's burgeoning innovative biotech industry and discussed the growing interest of BIO's seeking new or expanded partnerships with Indian firms.
China To Invest $1 Billion To Ramp Up New Drug Innovation
SHANGHAI - China will invest RMB 6.6 billion ($960 million) to launch a massive new drug development and manufacturing program from 2008 to 2010. Roughly 3,290 projects focused on preclinical studies and identifying new candidates are awaiting approval to initiate in 2009